MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS

Authors :: Evan Y. Yu
Johann S. de Bono
Charles Schloss
Ali Tafreshi
Gwenaelle Gravis
Michael Stoeckle
Howard Gurney
Josep M. Piulats
Marinela Augustin
Joan Carles
Xin Tong Li
Christian Heinrich Poehlein
Luke T. Nordquist
Brigitte Laguerre
Tilman Todenhoefer
Christophe Massard
Peter C.C. Fong
Jose Angel Arranz Arija
Michael Kolinsky
Stéphane Oudard
Source :: Journal of Urology. 206
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.
Abstract: INTRODUCTION AND OBJECTIVE:The phase 1/2 KEYNOTE-365 study (NCT02861573) previously showed that pembro+olaparib was associated with antitumor activity and acceptable safety in molecularly unselecte...

Subjects :: Antitumor activity
Oncology
medicine.medical_specialty
business.industry
Urology
Pembrolizumab
Castration resistant
medicine.disease
Olaparib
chemistry.chemical_compound
Prostate cancer
Docetaxel
chemistry
Internal medicine
Cohort
medicine
In patient
business
medicine.drug

Tools